Latest Intellectual Property News

Zoono Group Limited has closed its recent rights issue, raising $785,000 with a significant shortfall remaining. Managing Director Paul Hyslop fully subscribed and may provide further financial support as the company targets growth in Asia and product innovation.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.

FBR Limited has secured a significant $7.8 million memorandum of understanding for its Hadrian X® robotic bricklayer and launched a new DST®-enabled welding robot, Mantis, while advancing automation projects with Samsung Heavy Industries.

Identitii Limited advances its BNDRY AML platform tailored for clubs and pubs through strategic collaborations and new funding, while managing cash flow pressures and legal challenges.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Nanollose Limited has completed a successful pilot manufacturing run blending its Nullarbor-20 fibre with wool, raised $1.05 million through an entitlement issue, and appointed Andrew Moullin as CEO to drive its commercialisation strategy.

Advanced Health Intelligence Ltd has locked in up to AUD 5.5 million from Oakley Capital Partners, reinforcing its capital base as it pushes toward reinstatement on the ASX and broader growth ambitions.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

KNeoMedia reports steady progress toward ASX reinstatement, underpinned by successful capital raises and significant expansion of its KneoScience educational platform in partnership with the New York City Department of Education.

Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.